Any current/future new fundraising through debt or equity?

Currently, Shaily Engineering Plastics Limited is not raising any capital immediately; the recent resolution for fundraise is an enablement option for future needs. The company is preparing for potential large-scale, time-sensitive, capital-intensive projects, especially for additional device manufacturing capacities. If such an opportunity arises, they want the ability to quickly raise capital, either through debt or equity, as this would require substantial one-off capex. There is no mention of an ongoing or imminent fundraising, but readiness is maintained to act swiftly if required.

Any current/future capex/capital investment/strategic investment?

The company is evaluating setting up a new plant for consumer electronics, with an initial estimated capex of around INR 100 crores. Additional substantial capex is expected for scaling new device capacities, including healthcare-related projects that cannot be serviced from existing sites like India or Abu Dhabi. A capital raising resolution is in place as an enablement option for time-sensitive, capital-intensive projects, though no immediate capital is being raised. There is ongoing investment in the new pen injector production lines, with capacity being added (25 million pens added in Marc

Future growth expectations in sales/revenue/volumes?

Healthcare segment revenue grew 139% in FY26 to INR393 crores, driven by pen injector ramp-up and GLP-1 product launches in India, Canada, and upcoming other countries. Pen injector order of INR423 crores is spread over 4 years, with regular supplies expected to ramp up. Total pen injector capacity expected to reach 80 million pens by July-August FY27, targeting 36 million pens supply in FY27 and around 50 million pens in FY28. Full utilization of pen injector capacity anticipated within next 2-3 years, with healthcare segment expected to sustain strong growth. Consumer segment declined 9% in

Future growth expectations in earnings/operating earnings/profits/EPS?

FY26 marked by smooth execution and improved operational performance; confident of profitable, sustainable growth in coming years (Amit Sanghvi, closing remarks). Healthcare vertical expected to continue scaling with GLP-1 product launches in India, Canada, and other countries driving regular supply ramp-up. Consumer segment will depend on global demand recovery; new product additions in consumer electronics and semiconductor trays aim to restore growth momentum. Capacity additions (50 million pens planned by July/August) should enable healthcare revenue growth but exact quarterly run rate gui

IN US

Sale is live|00:00:00left today

Shaily Engineering Plastics LtdQ1 FY26Consumer Durables

Shaily Engineering Plastics Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,850P/E: 89.5Market Cap: ₹12.7K CrSector: Consumer Durables

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Healthcare segment revenue grew 139% in FY26 to INR393 crores, driven by pen injector ramp-up and GLP-1 product launches in India, Canada, and upcoming other countries.
→Pen injector order of INR423 crores is spread over 4 years, with regular supplies expected to ramp up.
→Total pen injector capacity expected to reach 80 million pens by July-August FY27, targeting 36 million pens supply in FY27 and around 50 million pens in FY28.
→Full utilization of pen injector capacity anticipated within next 2-3 years, with healthcare segment expected to sustain strong growth.
→Consumer segment declined 9% in FY26 but expected to recover as global demand improves; new products being added to consumer space.
→Industrial segment growing steadily with 41% growth in FY26.
→Overall, company targets ~25% consolidated top-line growth, dependent on healthcare ramp-up and consumer recovery.

Margin guidance

Category 3

→FY26 marked by smooth execution and improved operational performance; confident of profitable, sustainable growth in coming years (Amit Sanghvi, closing remarks).
→Healthcare vertical expected to continue scaling with GLP-1 product launches in India, Canada, and other countries driving regular supply ramp-up.
→Consumer segment will depend on global demand recovery; new product additions in consumer electronics and semiconductor trays aim to restore growth momentum.
→Capacity additions (50 million pens planned by July/August) should enable healthcare revenue growth but exact quarterly run rate guidance not disclosed.
→UK subsidiary margins expected to be maintained over long term with focus on advanced device projects; combined UK and UAE operations should deliver stable margins.
→Operating efficiencies improving; machine utilization up to 47.6% in FY26 from 42.2% last year.
→Management expects growth bounce back in consumer segment and continuation of healthcare growth to sustain consolidated top-line growth around 25%.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Currently, Shaily Engineering Plastics Limited is not raising any capital immediately; the recent resolution for fundraise is an enablement option for future needs.
→The company is preparing for potential large-scale, time-sensitive, capital-intensive projects, especially for additional device manufacturing capacities.
→If such an opportunity arises, they want the ability to quickly raise capital, either through debt or equity, as this would require substantial one-off capex.
→There is no mention of an ongoing or imminent fundraising, but readiness is maintained to act swiftly if required.

Order book

Yes

- The company has a recently announced INR 423 crore pen injector order spread over 4 years (Q4 FY26 transcript). - The order is incremental and for pen injector supplies over 4 years. - For FY27, guidance is around 36 million pens for pen injector supplies. - Existing capacity for pen injectors is 30 million pens; an additional 25 million was added in March and another 25 million expected by July/August, totaling 80 million pens capacity. - The healthcare revenue ramp-up is expected with new product launches in India, Canada, and upcoming launches in other countries. - The consumer segment saw a decline and is expected to recover as global demand improves. - Semiconductor trays order currently from a Korean client with plans to supply to other semiconductor manufacturers in India. - UK subsidiary focusing on longer-term projects; revenue growth expected over time but currently with lower quarter margins. Overall, orderbook includes the INR 423 crore pen injector order plus ongoing orders in healthcare and semiconductor segments.

Capex plans

Yes

→The company is evaluating setting up a new plant for consumer electronics, with an initial estimated capex of around INR 100 crores.
→Additional substantial capex is expected for scaling new device capacities, including healthcare-related projects that cannot be serviced from existing sites like India or Abu Dhabi.
→A capital raising resolution is in place as an enablement option for time-sensitive, capital-intensive projects, though no immediate capital is being raised.
→There is ongoing investment in the new pen injector production lines, with capacity being added (25 million pens added in March, another 25 million expected by July-August).
→Expansion plans include increasing operational efficiency and capacity utilization, targeting 35-40 million pens in supply by FY28.
→The company is progressing with projects in Abu Dhabi to leverage operational cost advantages and global talent availability.

How does Shaily Engineering Plastics Ltd rank vs peers in Consumer Durables?

Pro feature

1Shaily Engineering Plastics Ltd

Rev 2Mar 3

See full Consumer Durables sector rankings

Want more stocks like Shaily Engineering Plastics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio